Navigation Links
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Date:7/22/2008

e results led to the initiation of a Phase II liver cancer trial that is now open in the U.S., and will shortly begin enrolling patients at sites in South Korea and Canada, as well.

About JX-594

JX-594 is a cancer biotherapeutic, currently in Phase II trials, from a proprietary class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types in three Phase I trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program against smallpox. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase II trial for primary liver cancer, demonstrated promising Pha
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
2. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Germany , and ... , Exclusive global license from ... SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for ... be targeted by new test, indicate favorable prognosis for ... QIAGEN sees potential for developing companion diagnostics ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, ... provider of medication and supply management solutions and ... call Thursday, July 31, to discuss the Company,s ... Omnicell Second Quarter 2014 earnings conference call and ... PTWho:  , Randall Lipps, chairman, president and chief ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... 2011 Masimo (NASDAQ: ... of Health & Human Services (HHS) has added Critical ... as a national newborn screening standard.  In addition, the ... detection, published online in the Lancet (appearing ...
... or the "Company") (NASDAQ: UNIS ; ASX: UNS) ... to purchase an additional U.S. $500,000 in shares of the ... 30th. These purchases of Unilife shares will be part of ... $1.0 million in shares by September 30th. This ...
Cached Medicine Technology:U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 2U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 3U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 4U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 5U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 6U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 7U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 8U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 9U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 10Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011 2Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011 3
(Date:7/25/2014)... 2014 Reproductive Science Center (RSC) of ... Kerri Luzzo, Lead Physician at RSC Rhode Island, received ... accomplishments in fertility care and community outreach issued by ... Annual PBN Awards ceremony held July 24th at Salve ... most highly regarded, emerging leaders in their field were ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- The human brain can ... dehydration, a new study finds. Although dehydration ... England have found that the brain compensates by increasing ... "This research has helped us understand a lot ... exercise in extreme conditions," study first author Steven Trangmar, ...
(Date:7/25/2014)... ON (PRWEB) July 25, 2014 A new ... Hospital revealed that 39 percent of all children in the ... dentist. , The survey looked at 2,505 children during the years ... around four years of age. The final result was that ... dental care. Many of these children were from lower-income families and ...
(Date:7/25/2014)... On July 22, 2014, CEDR ... the nation’s number one provider of legally-compliant, individually ... partnership with TransAct Merchant Solutions’ National Association Program ... Chase Paymentech Solutions, LLC, which provides sales and ... are members of TransAct’s National Association Program (NAP) ...
(Date:7/25/2014)... Philadelphia, PA (PRWEB) July 25, 2014 ... that Valerie D. Weber, MD, MS, FACP, has been appointed ... , Weber will join Drexel from The Commonwealth Medical College, ... Sciences, associate dean for clinical affairs, and professor of medicine. ... of The Commonwealth Medical College, Weber had a major role ...
Breaking Medicine News(10 mins):Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3
... drink and fight than females, study finds , WEDNESDAY, ... healthy behaviors, boys, high school team sports might be doing ... teenage boys, participation in team sports may encourage unruly behavior ... the other hand, seem to behave better in organized sports, ...
... than women if spouse is sick, study finds , WEDNESDAY, Nov. ... a marriage, and couples are much more likely to fall apart ... of separation or divorce are six times higher compared to when ... shows. , The researchers did find that couples that have been ...
... need to use the antiviral properly, experts say , WEDNESDAY, ... in a Canadian family developed a strain of the H1N1 ... being given the drug to prevent the disease. , To ... of H1N1 swine flu that were resistant to Tamiflu, which ...
... ... desperate pioneers whose drug use had gotten the better of them every day ... an epilepsy drug could reduce their use of cocaine. In the end, 14 ... final three weeks of the study with no signs of cocaine use on ...
... For Lung Cancer Legislation , WASHINGTON, Nov. 11 ... on Veterans Day and announces the launch of a ... cancer -- the leading cause of cancer death among ... , LCA also announces that major veteran service organizations ...
... The University of Rochester Medical Center has announced ... researchers studying the electrical activity of the heart with ... and developing new electrocardiograph technologies. The Center for ... $2.3 million grant from the National Institutes of Health ...
Cached Medicine News:Health News:Boys' Team Sports May Encourage Bad Behavior 2Health News:Boys' Team Sports May Encourage Bad Behavior 3Health News:Cancer Can Strain Marriages to Breaking Point 2Health News:Tamiflu-Resistant Swine Flu Found in Canadian Father 2Health News:Tamiflu-Resistant Swine Flu Found in Canadian Father 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 2Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 4Health News:Lung Cancer Alliance Salutes Veterans 2Health News:New Research Center to Focus on Cardiac Safety and Innovation 2Health News:New Research Center to Focus on Cardiac Safety and Innovation 3
Half Trial Frames with precision engineering and lightweight material....
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Child...
... Universal Trial Frame comes at a very attractive price. ,The ... Temple length 4 1/8" to 5 1/2" (98 to ... to 30, PD adjustable 24 to 40mm on each ... on each lens: left - 120 to 0 to 135 ...
Medicine Products: